Pfizer to start $500M biotech hedge fund

Pfizer is launching a hedge fund that will funnel $500 million into biotech companies, according to a June 2 news release from the pharma giant.

The hedge fund, named the Pfizer Breakthrough Growth Initiative, seeks to pursue new partnerships by funding biotech companies' research, manufacturing and growth.

Pfizer's chief business officer, John Young, noted the need to invest in new therapies amid the pandemic. "There has never been a more important moment to pursue new collaborations in our industry," he said in the press release.

More articles on pharmacy:
5 recent CMS pharmacy policy changes
Eli Lilly testing COVID-19 drug derived from survivor blood
Some pandemic-inspired FDA changes will stick, commissioner says

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Webinars

Featured Whitepapers